Treatment of Lambert-Eaton Syndrome With 3,4 DAP

Status:

NO_LONGER_AVAILABLE

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

Lead Sponsor:

David P. Richman, MD

Collaborating Sponsors:

Jacobus Pharmaceutical

Conditions:

Lambert Eaton Myasthenic Syndrome

Eligibility:

All Genders

18+ years

Brief Summary

A new drug called 3,4-Diaminopyridine (3,4-DAP) is currently under investigation for treatment of the symptoms of Lambert-Eaton Myasthenic Syndrome (LEMS). This is an expanded access trial, which mean...

Detailed Description

Patients with clinically-confirmed LEMS will receive 3, 4-DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg, three times a day and will increase by 50% every two weeks to 10-15 m...

Eligibility Criteria

Inclusion

Be 18 years or older, diagnosed with LEMS
If female, have negative pregnancy test and if premenopausal, be willing to practice an effective form of birth control during the study.

Exclusion

Is known to have a sensitivity to 3, 4 DAP
Has a history of past or current seizures
Has a history of past or current severe asthma
Is believed by the investigator to be unable to comply with the protocol
Unable to give informed consent

Key Trial Info

Start Date :

Trial Type :

EXPANDED_ACCESS

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00704925

Last Update

October 30 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)